Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China
- PMID: 35950847
- PMCID: PMC9746472
- DOI: 10.1080/21645515.2022.2096375
Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China
Abstract
Background: Since 2008, Fujian province provided measles-rubella (MR) vaccine at 8 months followed by measles-mumps-rubella (MMR) vaccine at 18 months a one-dose mumps-containing-vaccine (MuCV) schedule. Several mumps outbreaks have occurred recently in Fujian. Serological surveillance can assess population immunity to mumps and identify risk factors for mumps.
Methods: We conducted a cross-sectional serosurvey of mumps IgG antibodies in the general population of Fujian Province in 2018 and compare results with a similar study conducted in 2009, when the routine schedule had no MuCV. We analyzed changes in mumps epidemiology after implementation of a one-dose MuCV vaccination strategy.
Results: Mumps seroprevalence was 78.6% (95% CI: 77.4-79.8), and the geometric mean concentration (GMC) of mumps antibodies was 245.8 IU/ml (95% CI:237.3-255.1). MuCV vaccination at 18 months resulted in increased seroprevalence and GMCs. Seroprevalence and GMCs varied by age, gender, and number of doses received. Except for children under 18 months, seroprevalence and GMCs were lowest among 10-15-year-olds. Each year after introduction of the one-dose MuCV vaccination policy, the highest incidence of mumps was among 4-6-year-olds and 9-15-year-olds, gradually shifting to older age groups.
Conclusion: A one-dose mumps-containing vaccine schedule does not provide sustained and stable mumps immunity in Fujian. To reduce the risk of mumps, we recommend supplementary vaccination of children without a history of receiving at least one MuCV dose or who are seronegative at 10-15 years of age.
Keywords: Geometric Mean Concentration (GMC); Mumps; measles-mumps-rubella vaccine (MMR); seroprevalence; vaccination.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.PLoS One. 2014 Feb 20;9(2):e89361. doi: 10.1371/journal.pone.0089361. eCollection 2014. PLoS One. 2014. PMID: 24586717 Free PMC article. Clinical Trial.
-
High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China.Hum Vaccin Immunother. 2020 Jul 2;16(7):1738-1742. doi: 10.1080/21645515.2019.1708162. Epub 2020 Jan 24. Hum Vaccin Immunother. 2020. PMID: 31977281 Free PMC article.
-
[Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Apr 6;51(4):336-340. doi: 10.3760/cma.j.issn.0253-9624.2017.04.011. Zhonghua Yu Fang Yi Xue Za Zhi. 2017. PMID: 28395468 Chinese.
-
Vaccines for measles, mumps, rubella, and varicella in children.Cochrane Database Syst Rev. 2020 Apr 20;4(4):CD004407. doi: 10.1002/14651858.CD004407.pub4. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Nov 22;11:CD004407. doi: 10.1002/14651858.CD004407.pub5. PMID: 32309885 Free PMC article. Updated.
-
Measles, mumps, rubella prevention: how can we do better?Expert Rev Vaccines. 2021 Jul;20(7):811-826. doi: 10.1080/14760584.2021.1927722. Epub 2021 Jun 7. Expert Rev Vaccines. 2021. PMID: 34096442 Review.
Cited by
-
Spatial Effect of Ecological Environmental Factors on Mumps in China during 2014-2018.Int J Environ Res Public Health. 2022 Nov 22;19(23):15429. doi: 10.3390/ijerph192315429. Int J Environ Res Public Health. 2022. PMID: 36497504 Free PMC article.
-
Effectiveness and safety of a mumps containing vaccine in preventing laboratory-confirmed mumps cases from 2002 to 2017: A meta-analysis.Open Life Sci. 2024 Feb 8;19(1):20220820. doi: 10.1515/biol-2022-0820. eCollection 2024. Open Life Sci. 2024. PMID: 38465337 Free PMC article.
-
Decade-long protection of the mumps vaccine: Insights from a large-scale serological study.PLoS Negl Trop Dis. 2025 Jun 3;19(6):e0013125. doi: 10.1371/journal.pntd.0013125. eCollection 2025 Jun. PLoS Negl Trop Dis. 2025. PMID: 40460365 Free PMC article.
-
Development and characterization of the genotype F attenuated mumps candidate strains.Front Immunol. 2025 Jul 22;16:1629585. doi: 10.3389/fimmu.2025.1629585. eCollection 2025. Front Immunol. 2025. PMID: 40766323 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical